Filtered By:
Therapy: Cancer Therapy
This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 390 results found since Jan 2013.
Fundraising Poster: Help the SENS Research Foundation Speed Progress Towards a Universal Therapy Effective for All Cancers
The SENS Research Foundation's 2016 crowdfunded research initiative is focused on progress towards a universal cure for all forms of cancer, and needs our help to hit its goals within the next six weeks. Here is a poster to help spread the word:
Today's cancer therapies are both expensive and highly specific. There are hundreds of types of cancer, and many of them can evolve to defeat any one therapy as it is delivered. The research community can greatly improve this state of affairs, however, as it is possible to build a truly universal cancer therapy - one that cancers cannot evolve resistance to - by bl...
Source: Fight Aging! - July 5, 2016 Category: Research Authors: Reason Tags: Activism, Advocacy and Education Source Type: blogs
Fight Aging! Newsletter, July 4th 2016
In conclusion, therefore, I can say with confidence that the future of aging research is extremely bright, both scientifically and medically. The pace of progress must now be sharply accelerated, via the injection of the funds that should for many years have been allocated at far higher a level than has actually occurred.
LATEST HEADLINES FROM FIGHT AGING!
AN INTERVIEW WITH LAURA DEMING OF THE LONGEVITY FUND
https://www.fightaging.org/archives/2016/06/an-interview-with-laura-deming-of-the-longevity-fund/
Laura Deming has worked with the SENS Research Foundation and others on the molecular biology of ...
Source: Fight Aging! - July 3, 2016 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Mutant p53 as a Potential Target Across Many Cancer Types
In the scientific commentary I'll point out today, the authors advocate for the expansion of efforts to target mutations of the cancer suppressor gene TP53, encoding the protein p53, as a path to cancer therapies that might be broadly applicable to many cancer types. As I've noted in the past, the biggest problem with the majority of today's cancer research isn't that it is challenging and expensive, but rather that the therapies resulting from these efforts are only applicable to one or a few of the hundreds of subtypes of cancer. This is no way to defeat cancer; there are too few scientists and too little funding to do t...
Source: Fight Aging! - June 30, 2016 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs
Fight Aging! Newsletter, June 27th 2016
In conclusion, we showed for the first time that 7-KC induces oxidative stress via lysosomal dysfunction, resulting in exacerbation of calcification.
CHIMERIC ANTIGEN RECEPTOR CANCER THERAPIES CAN NOW TARGET SOLID TUMORS
https://www.fightaging.org/archives/2016/06/chimeric-antigen-receptor-cancer-therapies-can-now-target-solid-tumors/
If the research community is to win in the fight to cure cancer, and win soon enough to matter for all of us, then the focus must be on technology platforms that can be easily and cheaply adapted to many different types of cancer. The biggest strategic problem in the field is tha...
Source: Fight Aging! - June 26, 2016 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Chimeric Antigen Receptor Cancer Therapies Can Now Target Solid Tumors
If the research community is to win in the fight to cure cancer, and win soon enough to matter for all of us, then the focus must be on technology platforms that can be easily and cheaply adapted to many different types of cancer. The biggest strategic problem in the field is that most of the expensive, time-consuming efforts to develop new therapies are only applicable to one or a few of the hundreds of types of cancer. Immunotherapies based on the use of chimeric antigen receptors are an incremental step towards solving this problem, an improvement on the present situation because this technology may cut the cost of tail...
Source: Fight Aging! - June 22, 2016 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Fight Aging! Newsletter, June 20th 2016
We examined the engraftment and differentiation of alkaline phosphatase-positive NSCs expanded from the postnatal subventricular zone (SVZ), 3 months after grafting into the intact young or aged rat hippocampus. Graft-derived cells engrafted robustly into both young and aged hippocampi. Although most graft-derived cells pervasively migrated into different hippocampal layers, the graft cores endured and contained graft-derived neurons.
The results demonstrate that advanced age of the host at the time of grafting has no major adverse effects on engraftment, migration, and differentiation of grafted subventricular zone...
Source: Fight Aging! - June 19, 2016 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Crowdfunding Steps Towards a Universal Cancer Therapy: Help the SENS Research Foundation to Identify Drug Candidates and Mechanisms to Suppress ALT
The next stage in this year's SENS rejuvenation research funding initiatives launches today: the SENS Research Foundation is crowdfunding a search for drug candidates and mechanisms that can attack all ALT cancers, those that abuse the alternative lengthening of telomeres (ALT) processes to grow. This is a part of the OncoSENS program, which seeks to produce the grounding for a universal cancer treatment platform, based on the one commonality known to be shared by all cancers, which is that cancer cells must lengthen their telomeres, one way or another. You may recall coverage of the SENS Research Foundation ALT research i...
Source: Fight Aging! - June 15, 2016 Category: Research Authors: Reason Tags: Activism, Advocacy and Education Source Type: blogs
Subverting Tumor Associated Macrophages in Order to Attack Cancer
Potential cancer therapies that can address many types of cancer should be a primary focus of the cancer research community. There are far too many varieties of cancer to do otherwise if the goal is rapid progress towards the control of cancer. In this early stage research, researchers report on an approach to using immune cells hijacked by cancerous tissue as a way to attack the cancer. This could in principle be applied to numerous types of cancer:
Along with attacking foreign pathogens like bacteria, macrophages also help the body's organs develop and its wounds heal. Their own behavior is fine-tuned by small m...
Source: Fight Aging! - June 14, 2016 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Fight Aging! Newsletter, June 6th 2016
This study teaches us that poor wound healing and wrinkling and sagging that occur in aging skin share similar mechanisms."
Reduced cell cohesiveness of outgrowths from eccrine sweat glands delays wound closure in elderly skin
Human skin heals more slowly in aged vs. young adults, but the mechanism for this delay is unclear. In humans, eccrine sweat glands (ESGs) and hair follicles underlying wounds generate cohesive keratinocyte outgrowths that expand to form the new epidermis. Our results confirm that the outgrowth of cells from ESGs is a major feature of repair in young skin. Strikingly, in aged skin, ...
Source: Fight Aging! - June 5, 2016 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Undergoing Chemotherapy or Radiotherapy is, Literally, a Damaging Experience, but are These Consequences a Form of Accelerated Aging?
In this study, the cytokines VEGFA and monocyte chemotactic protein-1 also significantly increased and remained elevated at 12 months, but telomere length was not affected. In a cross-sectional cohort of patients in the same study, prior chemotherapy exposure was independently associated with increased p16ink4a expression comparable to 10 years of chronologic aging.
"Don't get cancer" is great advice. It is a pity that it is so very hard to follow in practice. For my money the most important work in the cancer research community is that focused on building technology platforms that can be applied to either all or ...
Source: Fight Aging! - June 2, 2016 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs
Nanoparticles and RNA Used to Engineer an Immune Response to Cancer
An approach using nanoparticles to deliver RNA to immune cells, so as to kick off an immune response targeted to a specific cancer, has been in the news of late. Immunotherapies of a wide variety of types will form the basis for the coming generation of cancer therapies, the replacements for the present staples of chemotherapy and radiotherapy, but there is far too much work taking place to comment on every single project. It is a matter of accident rather than merit as to which research results receive greater or lesser attention from the public and the media. With the immune system being as complicated as it is, there ar...
Source: Fight Aging! - June 2, 2016 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Fast Medicine
By MARC-DAVID MUNK, MD
A diversion into the world of high fashion in this week’s post… It’s an area that everyone who knows me would admit I know nothing about. Nevertheless, here we go…
Martin Schulte, a Partner at Oliver Wyman management consultants, recently posted a fascinating article on, of all things, fashion industry supply chain management. It contains some interesting nuggets for healthcare.
Background: before the 1980’s, couture was customized, reserved for the wealthy, and slow to diffuse into popular culture from biannual fashion shows.
Two disruptive changes shook up the fashion industry...
Source: The Health Care Blog - May 31, 2016 Category: Consumer Health News Authors: John Irvine Tags: Uncategorized Fast Medicine Fast-Fashion Marc-David Munk Patient Source Type: blogs
NIH Asks for Input on NCAB Cancer Moonshot Blue Ribbon Panel
Recently, the National Institutes of Health (NIH) released a Request for Information (RFI), asking for both public and cancer research community input on the National Cancer Advisory Board (NCAB) Blue Ribbon Panel. The Blue Ribbon Panel is part of the National Cancer Moonshot Initiative, which is led by Vice President Joe Biden and aims to make more cancer therapies available, while continuing to improve cancer prevention and early detection. Additional details of the National Cancer Moonshot Initiative can be found at http://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative.
The purpose of the NCAB is t...
Source: Policy and Medicine - May 25, 2016 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
Is High Prescription Drug Spending Becoming Our New Normal?
This report concluded there was value in these therapies but also raised concerns about whether their effects will translate into lower rates of heart attack and stroke. Further, ICER concluded that a discount of 67 percent off the drugs’ list price would better represent their overall benefit. ICER’s assessment is still in draft form and it remains unclear whether the report will have any effect. Nevertheless, such work is a step in the right direction.
Other entities are developing alternative methods to evaluate prescription drugs. The American Society for Clinical Oncology has sought comment on its proposed val...
Source: Health Affairs Blog - May 17, 2016 Category: Health Management Authors: Leigh Purvis and Crystal Kuntz Tags: Costs and Spending Drugs and Medical Technology Featured Payment Policy Quality Big Pharma Biosimiliar Comparative Effectiveness FDA PCSK9 inhibitors Sovaldi specialty drugs Source Type: blogs
Fight Aging! Newsletter, May 2nd 2016
This study is the first CAR T-cell trial to infuse patients with an even mixture of two types of T cells (helper and killer cells, which work together to kill cancer). With the assurance that each patient gets the same mixture of cells, the researchers were able to come to conclusions about the effects of administering different doses of cells.
In 27 of 29 participants whose responses were evaluated a few weeks after the infusion, a high-sensitivity test could detect no trace of their cancer in their bone marrow. The CAR T cells eliminated cancers anywhere in the body they appeared. Of the two participants who did n...
Source: Fight Aging! - May 1, 2016 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
